Loading...
•
Dec 31, 2023
Heron Therapeutics Q4 2023 Earnings Report
Heron Therapeutics experienced positive momentum and increased sales trajectory in both acute care and oncology care franchises.
Key Takeaways
Heron Therapeutics reported increased sales in both acute care and oncology care franchises for Q4 2023. ZYNRELEF achieved a quarterly record of $5.6 million in net product sales. The company ended the year with $80.4 million in cash and cash equivalents.
Oncology care franchise revenue exceeded full-year 2023 guidance.
ZYNRELEF achieved a quarterly record of $5.6 million in Q4 net product sales.
Ended 2023 with cash and cash equivalents of $80.4 million.
Partnership with CrossLink Life Sciences, LLC to expand ZYNRELEF promotional efforts was announced.
Revenue by Segment
Forward Guidance
The Company reaffirms its full-year 2024 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA.
Positive Outlook
- Product Revenues, Net $138.0 to $158.0 million
- Adjusted Operating Expenses (Excluding Stock-Based Compensation and Depreciation and Amortization) $108.0 to $116.0 million
- Adjusted EBITDA (Excluding Stock-Based Compensation and Depreciation and Amortization) $(22.0) to $3.0 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...